LaTrobe University – Olivia Newton-John Cancer Research Institute
About
La Trobe University’s Olivia Newton-John Cancer Research Institute (ONJCRI) is at the frontier of cancer medicine discovery and clinical trials, providing patients with access to experimental and breakthrough treatments including immunotherapies, targeted therapies and personalised medicine.
We support national collaboration of researchers in university and medical research institutes with integrated molecular imaging programs that extend from laboratory research, including biology, chemistry, biotechnology, through to novel probe radiochemistry and validation in animal imaging (PET and MRI) prior to human trials.
The validation of PET probes developed in the cyclotron and radiochemistry facilities on this campus has led to the initiation of over 20 first-in-human and later stage clinical trials in multiple sites in Melbourne, as well as Sydney, Perth, Brisbane and Adelaide collaborative sites.
Location
Olivia Newton-John Cancer Centre
145 Studley Rd
Heidelberg VIC 3084
Node Director
Contact
Latest news
NIF infrastructure underpins new Centre of Precision Medicine
24 July 2025
WHO adopts resolution to improve access to medical imaging globally
26 May 2025
New molecular-imaging network launched to benefit cancer, dementia imaging and new radiopharmaceuticals
26 May 2025
Radiotherapy and Theranostics: A Lancet Oncology Commission
07 October 2024
Publications
Lancet Oncology Commission on Radiotherapy and Theranostics
May Abdel-Wahab, MD PhD; Francesco Giammarile, MD PhD; Mauro Carrara, PhD; Diana Paez, MD; Hedvig Hricak, MD PhD; Nayyereh Ayati, PhD; Jing Jing Li, MCE; Malina Mueller, PhD; Ajay Aggarwal, MD PhD; Akram Al-Ibraheem, MD; Sondos Alkhatib, MD; Rifat Atun; Abubakar Bello, MD; Daniel Berger, PhD; Roberto C. Delgado Bolton, MD PhD; John M. Buatti, MD; Graeme Burt, PhD; Olivera Ciraj Bjelac, PhD; Lisbeth Cordero-Mendez, MD; Manjit Dosanjh, PhD; Thomas Eichler, MD; Elena Fidarova, MD; Soehartati Gondhowiardjo, MD PhD; et al.
Read Publication
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993
Ingrid Julienne Georgette Burvenich, Christian Werner Wichmann, Alexander Franklin McDonald, Nancy Guo, Angela Rigopoulos, Nhi Huynh, Mary Vail, Stacey Allen, Graeme Joseph O’Keefe, Fiona Elizabeth Scott, Raul Soikes, Steven Angelides, Reinhard von Roemeling & Andrew Mark Scott
Read Publication